Follow us

Donor Center
Donor Center on FacebookGoogle+

BioResearch
TwitterFacebook

Corporate
LinkedinGoogle+

HemaCare Corporation

Welcome to HemaCare Corporation – a leading global provider of biological blood products and services since 1978.

HemaCare Corporation is a leading blood products and services company serving healthcare providers and the scientific community for over 35 years. HemaCare performs therapeutic apheresis services, provides human-derived primary blood cells and tissues for advanced biomedical research, supports cell therapy clinical trials and commercialization with apheresis collections, and provides a wide range of consulting services in SOP development, personnel training, and quality and regulatory compliance. Learn more

BIORESEARCH PRODUCTS

HemaCare provides a variety of quality, controlled, consistent, viable human primary cells and blood components derived from an assortment of tissues. Our cell processing lab is capable of purifying lymphocytes, monocytes, neutrophils, CD34+ stem cells, and much more!

View our BioResearch Products Catalog

 

CELLULAR THERAPY

Quality of living cellular raw material is a major determinant of final product characteristics. Controlling and qualifying the cell collection step is essential to minimizing operational sources of variability, and greatly increases the likelihood of success in manufacturing. HemaCare’s specialty is apheresis collection, and, building on over 35 years of experience, has addressed this need for optimized cell collection with a program for controlling and qualifying its apheresis procedures and collection sites, bringing a higher degree of reproducibility to research projects or manufacturing efforts based on cGMP and cGTP principles.

Optimizing Apheresis Cellular Collections
Click here to view the presentation

THERAPEUTIC APHERESIS SAMPLE ORDER FORMS

ANNOUNCEMENTS

 

Events

5.10.2013 HemaCare will be exhibiting at the 2013 ASH Annual Meeting and Exposition taking place from December 7-10, 2013, in New Orleans, LA. Stop by booth #3021 to meet the HemaCare team and learn more about our NEW products and services and enter for a chance to win a prize! For more information on the meeting, please visit ASH's official website at www.hematology.org.

Company News

News

Thu, 02 Jan 2014 12:25:10 GMT

SEA Antagonizes the Imatinib-Meditated Inhibitory Effects on T Cell Activation via the TCR Signaling Pathway

Fri, 15 Nov 2013 14:46:08 GMT

Life Stem Genetics Announces James Vanden Bosch as Chief Medical Stem Cell Specialist

Wed, 13 Nov 2013 23:50:10 GMT

BioLife Solutions Announces $2.2 million Total Revenue for the Third Quarter of 2013

Wed, 13 Nov 2013 08:42:35 GMT

Argos Therapeutics Presents Data Showing Personalized Immunotherapy Correlates with Overall Survival Benefit in Metastatic Renal Cell Carcinoma

Thu, 31 Oct 2013 01:03:30 GMT

Janssen files EMA marketing authorisation application for blood cancer medicine Ibrutinib

Wed, 30 Oct 2013 22:00:00 GMT

Early HIV Treatment a Win-Win, Researchers Report

Wed, 30 Oct 2013 13:28:46 GMT

Researchers identify way to increase gene therapy success

Tue, 29 Oct 2013 21:21:23 GMT

Research in the News: Study uncovers potential to alleviate tissue damage during strokes or transplant

Mon, 28 Oct 2013 17:00:00 GMT

Juventas Therapeutics completes enrollment of Phase II STOP-HF study of JVS-100 in patients with symptomatic heart failure

Mon, 28 Oct 2013 15:55:46 GMT

Sangamo BioSciences, Inc. (SGMO) Presents Clinical Data From HIV Study Demonstrating Sustained Control of Viremia

Fri, 25 Oct 2013 14:54:46 GMT

Healing Damaged Hearts With Stem Cell Implants Gets New Technique

Wed, 23 Oct 2013 14:51:41 GMT

Cardio3 BioSciences Receives Authorization to Enroll Patients in Italy in its Phase III Clinical Trial CHART-1

Wed, 23 Oct 2013 12:21:29 GMT

Advaxis Announces First Patient Dosed with ADXS-HPV in Head and Neck Cancer Study

Wed, 23 Oct 2013 12:02:48 GMT

Terumo BCT Awarded Cost-Share Contract Worth Up to $29.9M for Research and Development Effort with the U.S. Department of DefenseTerumo BCT Awarded Cost-Share Contract Worth Up to $29.9M for Research and Development Effort with the U.S. Department of

Wed, 23 Oct 2013 06:29:38 GMT

Converting fat cells from liposection to liver cells in nine days — a regenerative medicine breakthrough

E-NEWSLETTER SIGN UP